Tuesday, 22 Jul 2025
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Subscribe
Life Care News
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
    NewsShow More
    AV-Comparatives Publishes World’s Largest Independent Enterprise Cybersecurity Solution Test
    AV-Comparatives Publishes World’s Largest Independent Enterprise Cybersecurity Solution Test
    22/07/2025
    VEOCEL’s Lyocell Fibers for Enhanced Cleaning Take Center Stage at World of Wipes 2025
    VEOCEL’s Lyocell Fibers for Enhanced Cleaning Take Center Stage at World of Wipes 2025
    22/07/2025
    VEOCEL’s Lyocell Fibers for Enhanced Cleaning Take Center Stage at World of Wipes 2025
    Talos to Acquire Coin Metrics Creating Industry’s First Integrated Data and Investment Management Platform for Digital Assets
    20/07/2025
    Euroclear reports robust H1 2025 results
    Euroclear reports robust H1 2025 results
    19/07/2025
    Synopsys Completes Acquisition of Ansys
    Synopsys Completes Acquisition of Ansys
    19/07/2025
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
  • 🔥
  • june
  • news
  • global
  • Business
  • july
  • today
  • announced
  • Tech
  • company
  • will
Font ResizerAa
Life Care NewsLife Care News
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Search
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Health

Addex Convenes Annual General Meeting 2025

GlobeNews Wire
Last updated: 03/06/2025 11:56 AM
GlobeNews Wire
Share
5 Min Read
Addex Convenes Annual General Meeting 2025
SHARE
Addex Convenes Annual General Meeting 2025

June 03, 2025 01:00 ET  | Source: Addex Therapeutics

Geneva, Switzerland, June 3, 2025 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its 2025 Annual General Meeting will take place on Tuesday June 24, 2025, at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am).

Agenda

1.   Approval of the Annual Report, the Annual Financial Statements and the Consolidated Financial Statements for the business year 2024

2.   Consultative vote on the Compensation Report for the business year 2024

3.   Appropriation of the results

4.   Discharge of the members of the Board of Directors and of the Executive Management

5.   Re-elections of the members of the Board of Directors and re-election of the Chairman of the Board of Directors

5.1.    Re-election of Vincent Lawton as member and Chairman of the Board of Directors
5.2.    Re-election of Raymond Hill as member of the Board of Directors
5.3.    Re-election of Timothy Dyer as member of the Board of Directors
5.4.    Re-election of Roger Mills as member of the Board of Directors
5.5.    Re-election of Jake Nunn as member of the Board of Directors
5.6.    Re-election of Isaac Manke as member of the Board of Directors

6.   Re-elections of the members of the Compensation Committee

6.1.    Re-election of Vincent Lawton as member of the Compensation Committee
6.2.    Re-election of Raymond Hill as member of the Compensation Committee

7.   Re-election of the Auditors

8.   Re-election of the Independent Voting Rights Representative

9.   Approval of the compensation of the members of the Board of Directors and of the Executive Management

9.1.    Compensation of the members of the Board of Directors
9.2.    Compensation of the members of the Executive Management

10.   Miscellaneous

The full invitation to the AGM 2025 may be found in the General Meetings section of the Company’s website

here

.

About Addex:

Addex is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex’s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex’s partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex also holds a 20% equity interest in a private spin out company, Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, mGlu7 NAM for mood disorders and mGlu2 NAM for mild neurocognitive disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol “ADXN” on each exchange. For more information, visit www.addextherapeutics.com

Contacts:

Addex Forward Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Addex Therapeutics’ Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics’ views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.

Bybit Private Wealth Management’s Top Performing Fund Delivered 12.66% APR in May
Olympic Day 2025: Lets Move? together for more motivation, community and joy
Hungarian President visits Olympic House and Olympic Museum
DDB Worldwide Named Cannes Lions 2025 Network of the Year for the Second Time in Two Years
AV-Comparatives Validates Real-World Threat Detection in 2025 EDR XDR MDR Certification Testing
TAGGED:addexAdventureadxnallostericannouncedannualbiopharmaceuticalclinicalstagecompanydevelopingdisordersfocusedgeneralgenevajunemeetingmodulatorsmoleculenasdaqneurologicalnovelportfoliosixsmallsourceswitzerlandtaketherapeuticstodaywill
Share This Article
Facebook Copy Link Print
- Advertisement -

Your Trusted Source for Accurate and Timely Updates!

Our commitment to accuracy, impartiality, and delivering breaking news as it happens has earned us the trust of a vast audience. Stay ahead with real-time updates on the latest events, trends.
FacebookLike
XFollow
PinterestPin
InstagramFollow
YoutubeSubscribe
LinkedInFollow
MediumFollow

Most Selling Products

Top Picks, Trending Now – Discover the Best Sellers!
Tecno Camon 20 Premier 5G

Tecno Camon 20 Premier 5G

Dark Welkin | 8GB RAM + 512GB Storage (Expandable RAM up to 16GB) | Industry’s 1st 50MP RGBW-Pro Camera | Segment-First 108MP Ultra-Wide Macro Lens | 6.67" 120Hz 10-bit AMOLED In-Display

iQOO Z10 Lite 5G

iQOO Z10 Lite 5G

Titanium Blue | 6GB RAM + 128GB Storage | Dimensity 6300 5G with 433K+ AnTuTu Score | Robust 6000mAh Battery | IP64 Rated + Military-Grade Shock Resistance

OnePlus 13s

OnePlus 13s

Black Velvet | 12GB RAM + 256GB Storage | Flagship Snapdragon® 8 Elite Chipset | Exceptional Battery Life in a Compact Form | Lifetime Display Warranty Included

Samsung Galaxy A55 5G

Samsung Galaxy A55 5G

Awesome Iceblue | 8GB RAM + 256GB Storage | Premium Metal Frame | 50MP OIS Main Camera with Nightography | IP67 Water & Dust Resistance | Gorilla Glass Victus+ | sAMOLED Display with Vision Booster

You Might Also Like

Red FM Announces Season 3 of the Quiz India Movement – The Ultimate T20 League Quiz Challenge
Entertainment

Red FM Announces Season 3 of the Quiz India Movement – The Ultimate T20 League Quiz Challenge

06/07/2025
WISeKey to Present at Maxim Tech Conference Discover the Innovations Reshaping Tomorrow on June 3 at 8:30am ET
Tech

WISeKey to Present at Maxim Tech Conference Discover the Innovations Reshaping Tomorrow on June 3 at 8:30am ET

02/06/2025
Presidio Named AWS Generative AI Innovation Alliance Partner
Tech

Presidio Named AWS Generative AI Innovation Alliance Partner

08/07/2025
ITM and ILL Extend Collaboration on the Manufacturing and Supply of Medical Lutetium-177 Radioisotope
Health

ITM and ILL Extend Collaboration on the Manufacturing and Supply of Medical Lutetium-177 Radioisotope

16/06/2025
Life Care News
Facebook Twitter Youtube Rss Medium

Life Care News:


We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.

Top Categories
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Usefull Links
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Copyright © 2015 – 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Life Care NewsLife Care News
Copyright © 2015 - 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?